Full Text:
영남의대학술지 Vol.28 No.1 p99-104, June 2011
Case Report
식도정맥류 출혈과 다발성 혈전증으로 발견된 본태성 혈소판 증다증 1예
A Case of Essential Thrombocythemia Presenting as Esophageal Varix Bleeding and Multiple Thrombosis
윤소연, 최준혁, 강선미, 조정남, 배성화, 류헌모
대구가톨릭대학교 의과대학 혈액종양학교실
교신저자：류헌모, 대구광역시 남구 대명4동 3056-6, 대구가톨릭대학교 의과대학 혈액종양학교실
Tel: (053) 650-4034, Fax: (053) 622-6062
E-mail : rhmrhm@cu.ac.kr
June 30, 2011
Abstract
Essential thrombocythemia (ET), a subcategory of chronic myeloproliferative disorder, is characterized by absolute thrombocytosis due to excessive clonal proliferation of platelets, hyperaggregability of platelets, and increased incidence of thrombosis and hemorrhage. We consider a diagnosis of ET when an unexplained and persistent thrombocytosis is observed. It is difficult to consider ET first when we meet a patient with esophageal varix bleeding or unusual multiple thromboses like mesenteric vein, splenic vein, and portal vein. This article reports a patient who presented initially with esophageal varix bleeding and unusual multiple thromboses, thereafter, she was diagnosed with ET after testing positive for the Janus Tyrosine Kinase 2 (JAK2) V617F mutation. In conclusion, in patients with varix bleeding and unusual multiple thromboses, myeloproliferative disorders like essential thrombocythemia should be considered as a potential cause and testing for the JAK2 mutation is warranted.
Key Words: Essential thrombocythemia, Esophageal varix, Thrombosis, JAK2
References
	1. Bain BJ, Clark DM. Bone marrow pathology. 3rd ed. Oxford: Blackwell Science; 2001.
	2. Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol 1993;83:198-203.
	3. Beer PA, Erber WN, Campbell PJ, Green AR. How I treat essential thrombocythemia. Blood 2011;117:1472-82.
	4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
	5. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
	6. Ahn JY, Yoo SJ, Bang SM, Park PW, Seo YH, Shin DB, et al. JAK2 V617F mutation in Korean patients with essential thrombocythemia. Korean J Lab Med 2007;27:77-82. Korean.
	7. Goldman L, Bennett JC. Cecil Textbook of Medicine, 20th ed. Philadelphia: Saunders; 1996.
	8. Gangat N, Wolanskyj AP, Tefferi A. Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur J Haematol 2006;77:327-33.
	9. Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007;5:55-61.
	10. Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007;5:859-61.
	11. de Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708-14.
	12. Guidelines on the investigation and management of thrombophilia. The British Committee for Standards in Haematology. J Clin Pathol 1990; 43:703-9.
	13. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988;94:1063-9.
	14. Carvajal S, Zapata R, Bertin P, Miquel JF. Portal vein thrombosis associated with essential thrombocytosis. Clinical cases and review of the literature. Rev Med Chil 1996;124:353-8.